文献速递泌尿系结石

比较经验性预防性药物治疗对肾结石病患者结石复发的影响

Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease.
PubMed 文献 · Urology · 2022-05-08

本研究利用2008至2018年工作年龄成人肾结石病医疗索赔数据,比较经验性使用噻嗪类、枸橼酸碱剂或别嘌醇患者的结石相关事件频率。队列包括1834例(60%)噻嗪类、654例(21%)枸橼酸碱剂和558例(18%)别嘌醇患者。调整后噻嗪类组结石事件发生率最低(14.8%),显著低于枸橼酸碱剂(20.4%)或别嘌醇(20.4%)(各P<.001);噻嗪类较别嘌醇结石事件3年内几率低32%(OR 0.68,95%CI 0.53-0.88),枸橼酸碱剂与别嘌醇无此关联(OR 1.00,95%CI 0.75-1.34)。

要点

  • 经验性噻嗪类治疗与后续结石相关事件几率显著降低相关(OR 0.68,95%CI 0.53-0.88 vs 别嘌醇)。
  • 枸橼酸碱剂与别嘌醇相比,结石事件几率无显著差异(OR 1.00,95%CI 0.75-1.34)。
  • 在无法进行24小时尿液检测时,噻嗪类可能优于枸橼酸碱剂或别嘌醇用于经验性预防性药物治疗。

核心结论

  • 经验性预防性药物治疗中,噻嗪类与后续结石相关事件几率显著降低相关。
  • 当24小时尿液检测不可用时,噻嗪类可能优于枸橼酸碱剂或别嘌醇用于经验性预防性药物治疗。

研究设计与样本

  • 使用2008至2018年工作年龄成人肾结石病诊断的医疗索赔数据。
  • 识别处方噻嗪类、枸橼酸碱剂或别嘌醇的患者,排除启动预防性药物治疗前接受24小时尿液检测者及随访不足3年者。
  • 拟合多变量回归模型估计结石相关事件(急诊就诊、住院或结石手术)与预防性药物类别的关联。

主要发现

  • 队列由1834例(60%)经验性处方噻嗪类、654例(21%)枸橼酸碱剂和558例(18%)别嘌醇的患者组成。
  • 控制患者因素(包括药物依从性和增加复发风险的共存疾病)后,任何结石事件的调整发生率在噻嗪类组最低(14.8%),枸橼酸碱剂组为20.4%,别嘌醇组为20.4%(各P<.001)。
  • 噻嗪类与别嘌醇相比,3年内后续结石事件几率低32%(OR 0.68,95%CI 0.53-0.88)。
  • 枸橼酸碱剂与别嘌醇相比,未观察到此类关联(OR 1.00,95%CI 0.75-1.34)。

临床怎么用

  • 作者认为,当24小时尿液检测不可用时,经验性预防性药物治疗中噻嗪类可能优于枸橼酸碱剂或别嘌醇。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the frequency of stone-related events among patients receiving thiazides, alkali citrate, and allopurinol without prior 24 h urine testing. It is unknown whether 1 preventative pharmacological therapy (PPT) medication class is more beneficial for reducing kidney stone recurrence when prescribed empirically. MATERIALS AND METHODS: Using medical claims data from working-age adults with kidney stone disease diagnoses (2008-2018), we identified those prescribed thiazides, alkali citrate, or allopurinol. We excluded those who received 24 h urine testing prior to initiating PPT and those with less than 3 years of follow-up. We fit multivariable regression models to estimate the association between the occurrence of a stone-related event (emergency department visit, hospitalization, or surgery for stones) and PPT medication class. RESULTS: Our cohort consisted of 1834 (60%), 654 (21%), and 558 (18%) patients empirically prescribed thiazides, alkali citrate, or allopurinol, respectively. After controlling for patient factors including medication adherence and concomitant conditions that increase recurrence risk, the adjusted rate of any stone event was lowest for the thiazide group (14.8%) compared to alkali citrate (20.4%) or allopurinol (20.4%) (each P < .001). Thiazides, compared to allopurinol, were associated with 32% lower odds of a subsequent stone event by 3 years (OR 0.68, 95% CI 0.53-0.88). No such association was observed when comparing alkali citrate to allopurinol (OR 1.00, 95% CI 0.75-1.34). CONCLUSION: Empiric PPT with thiazides is associated with significantly lower odds of subsequent stone-related events. When 24 h urine testing is unavailable, thiazides may be preferred over alkali citrate or allopurinol for empiric PPT.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Hsi RS, Yan PL, Crivelli JJ, et al. Comparison of Empiric Preventative Pharmacologic Therapies on Stone Recurrence Among Patients with Kidney Stone Disease. Urology. 2022. PMID: 35545149. doi:10.1016/j.urology.2022.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。